Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients

Published:2012-10-23 Issue:6 Volume:13 Page:484-489
ISSN:1470-269X
Container-title:The Pharmacogenomics Journal
language:en
Short-container-title:Pharmacogenomics J

Author:

Habtewold A,Amogne W,Makonnen E,Yimer G,Nylén H,Riedel K-D,Aderaye G,Bertilsson L,Burhenne J,Diczfalusy U,Aklillu E

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine

Link

http://www.nature.com/articles/tpj201246.pdf

Reference30 articles.

1. Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002; 72: 1–9.

2. Josephson F, Bertilsson L, Bottiger Y, Flamholc L, Gisslen M, Ormaasen V et al. CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4β-Hydroxycholesterol levels. Eur J Clin Pharmacol 2008; 64: 775–781.

3. Kanebratt KP, Diczfalusy U, Backstrom T, Sparve E, Bredberg E, Bottiger Y et al. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther 2008; 84: 589–594.

4. Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Bottiger Y, Bertilsson L . 4β-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol 2009; 67: 38–43.

5. Lutjohann D, Marinova M, Schneider B, Oldenburg J, von Bergmann K, Bieber T et al. 4β-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man. Int J Clin Pharmacol Ther 2009; 47: 709–715.

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Pharmacogenomics Studies for Precision Medicine Among Ethiopian Patients and Their Clinical Implications: A Scoping Review;Pharmacogenomics and Personalized Medicine;2024-07

2. Human Pharmacokinetic and CYP3A Drug–Drug Interaction Prediction of GDC-2394 Using Physiologically Based Pharmacokinetic Modeling and Biomarker Assessment;Drug Metabolism and Disposition;2024-05-29

3. Pharmacokinetics of Single-Dose Versus Double-Dose Dolutegravir After Switching From a Failing Efavirenz-Based Regimen;JAIDS Journal of Acquired Immune Deficiency Syndromes;2024-05-01

4. Influence of CYP2B6 Pharmacogenetics on Stereoselective Inhibition and Induction of Bupropion Metabolism by Efavirenz in Healthy Volunteers;Journal of Pharmacology and Experimental Therapeutics;2022-07-07

5. Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study;Journal of Personalized Medicine;2021-12-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3